DND-41 In Vitro Post-translational Modifications Assay

This assay is to provide DND-41-based In Vitro Post-translational Modifications Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

DND-41

Human

DND-41 was established from the peripheral blood of 13-year-old boy with T-acute lymphoblastic leukemia (T-ALL; type III cortical) in 1977; described to carry CDKN2B (p15INK4B) and CDKN2A (p16INK4A) deletions and TP53 (p53)mutation.

Acute Lymphoblastic Leukemia; ALL

Oncology

In Vitro Post-translational Modifications Assay

DND-41-cell based In Vitro Post-translational Modifications Assay

Immunoassays and mass spectrometry techniques are considered ideal techniques for the detection of post-translational modification. Both the genetic and epigenetic modifications have contributed to the initiation and progression of cancer.

Gene and Protein Expression Assays

Following transcription, primary transcript RNA is converted into mature RNA by post-transcriptional modifications. Post-transcriptional modification includes three major steps namely the addition of a 5'cap, addition of a 3'polyadenylation tail and RNA splicing. Stability of RNA has been considered as very important for gene expression and proteins at the post-transcriptional level.